Evidence map›Paper›PMID 26123562›Full record

ArticleThe Journal of infectious diseases2015

A Bivalent Vaccine Based on a PB2-Knockout Influenza Virus Protects Mice From Secondary Pneumococcal Pneumonia.

Ryuta Uraki, Zhenyu Piao, Yukihiro Akeda, Kiyoko Iwatsuki-Horimoto, Maki Kiso, Makoto Ozawa, Kazunori Oishi, Yoshihiro Kawaoka

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Ryuta UrakiDivision of Virology, Department of Microbiology and Immunology.
Zhenyu PiaoLaboratory of Clinical Research on Infectious Diseases, International Research Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University.
Yukihiro AkedaLaboratory of Clinical Research on Infectious Diseases, International Research Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University.
Kiyoko Iwatsuki-HorimotoDivision of Virology, Department of Microbiology and Immunology.
Maki KisoDivision of Virology, Department of Microbiology and Immunology.
Makoto OzawaLaboratory of Animal Hygiene Transboundary Animal Diseases Center, Joint Faculty of Veterinary Medicine, Kagoshima University.
Kazunori OishiInfectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo Laboratory of Clinical Research on Infectious Diseases, International Research Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University.
Yoshihiro KawaokaDivision of Virology, Department of Microbiology and Immunology Department of Special Pathogens, International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo ERATO Infection-Induced Host Responses Project (JST), Saitama, Japan Department of Pathobiological Sciences, University of Wisconsin-Madison.
Osaka University · JPKagoshima University · JPNational Center for Infectious Diseases · USSocial Insurance Saitama Chuo Hospital · JP

Funding

NIAID NIH HHS HHSN266200700010CPHS HHS HHSN266200700010C
6 · The paper itself

Abstract

backgroundSecondary bacterial infections after influenza can be a serious problem, especially in young children and the elderly, yet the efficacy of current vaccines is limited. Earlier work demonstrated that a replication-incompetent PB2-knockout (PB2-KO) influenza virus possessing a foreign gene in the coding region of its PB2 segment can serve as a platform for a bivalent vaccine.

methodsIn the current study, we generated the PB2-KO virus expressing pneumococcal surface protein A (PspA), PB2-KO-PspA virus, the replication of which is restricted to PB2-expressing cells. We then examined the protective efficacy of intranasal immunization with this virus as a bivalent vaccine in a mouse model.

resultsHigh levels of influenza virus-specific and PspA-specific antibodies were induced in the serum and airways of immunized mice. The intranasally immunized mice were protected from lethal doses of influenza virus or Streptococcus pneumoniae. These mice were also completely protected from secondary pneumococcal pneumonia after influenza virus infection.

conclusionsThese findings indicate that our recombinant influenza virus serves as a novel and powerful bivalent vaccine against primary and secondary pneumococcal pneumonia as well as influenza.

Indexed as

Administration, IntranasalAnimalsBacterial ProteinsCoinfectionDisease Models, AnimalGene Knockout TechniquesInfluenza VaccinesMiceOrthomyxoviridaeOrthomyxoviridae InfectionsPneumococcal VaccinesPneumonia, PneumococcalVaccines, SyntheticViral ProteinsBacterial ProteinsInfluenza VaccinesPB2 protein, influenza viruspneumococcal surface protein APneumococcal VaccinesVaccines, SyntheticViral Proteinsbivalent vaccinereplication-incompetent influenza virussecondary pneumococcal pneumonia

Identifiers

PMID26123562
PMCPMC4655860
OpenAlexW1895583853

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.